Switch to:
More From Other Websites
XENOPORT INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Oct 16 2014
XenoPort And NIAAA To Test Alcoholism Treatment Sep 10 2014
Xenoport/NIAAA Collaborate on Alcoholism Therapy Sep 10 2014
XenoPort to Present Data for Novel Fumarate Analog XP23829 at the 2014 Joint ACTRIMS-ECTRIMS Meeting... Sep 10 2014
XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment... Sep 09 2014
XenoPort to Present at the Morgan Stanley Global Healthcare Conference Sep 02 2014
XENOPORT INC Financials Aug 15 2014
XENOPORT INC Files SEC form 10-Q, Quarterly Report Aug 07 2014
XENOPORT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2014
XenoPort Reports Second Quarter Financial Results Aug 06 2014
Q2 2014 XenoPort, Inc. Earnings Release - After Market Close Aug 06 2014
XenoPort to Release Second Quarter Financial Results on August 6, 2014 Jul 22 2014
Immune Pharma: A Top-Pick Based On Pipeline And Valuation Jul 09 2014
XenoPort entitled to $20M upfront payment on license pact Jun 24 2014
XENOPORT INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Jun 24 2014
XenoPort's XP23829 in Phase II Study Jun 24 2014
XENOPORT INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 16 2014
Stockholders Elect ALL Three XenoPort Director Nominees at Annual Meeting Jun 11 2014
XenoPort to Present at the 2014 Wells Fargo Healthcare Conference Jun 09 2014
XenoPort Urges Stockholders to Vote "FOR ALL" XenoPort Director Nominees on the WHITE Proxy Card Jun 06 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK